Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) EBIT Margin Growth (1y) (2017 - 2023)

Analysis

Lite Strategy (LITS) EBIT Margin Growth (1y) (2017 - 2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (1y) (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 602.00
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn -16,814.00
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -143.00
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 78.00
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 1,135.00
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 7,666.00
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 2,002.00
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn -2,881.00
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -1.23 Mn
10 Lite Strategy 38.03 Mn 30.49 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2023 29,336.00
Jun 30, 2023 -61,857.00
Mar 31, 2023 -5,571.00
Dec 31, 2022 17,623.00
Sep 30, 2022 5,049.00
Jun 30, 2022 6,570.00
Mar 31, 2022 -2,020.00
Dec 31, 2021 -2,373.00
Sep 30, 2021 -6,663.00
Jun 30, 2021 -25,260.00
Mar 31, 2021 79,806.00
Dec 31, 2020 107,606.00
Sep 30, 2020 89,845.00
Jun 30, 2020 108,557.00
Mar 31, 2020 985.00
Dec 31, 2019 -62,306.00
Sep 30, 2019 96,493.00
Jun 30, 2019 32,312.00
Mar 31, 2019 38,806.00
Dec 31, 2018 114,579.00